Continuous Glucose Sensors: Dexcom's Over-the-Counter Launch in the US
Continuous Glucose Sensors Revolutionize Diabetes Management
Dexcom launched its over-the-counter continuous glucose monitor, Stelo, in the United States on Monday. Priced at up to $99, Stelo represents a significant development in diabetes care, making continuous glucose monitoring more accessible to a broader range of consumers.
FDA Approval and Market Impact
Cleared by the US health regulator, Stelo promises greater convenience for diabetes patients, eliminating the need for a prescription. This strategic move not only empowers users but is expected to influence the overall 'continuous glucose sensor' market.
- Key Features:
- Affordable at $99
- FDA-cleared for OTC use
Looking Ahead: Future Opportunities
The introduction of Stelo opens new avenues for healthcare innovation and diabetes management. As consumer awareness grows, Dexcom's product could redefine how individuals manage their glucose levels.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.